Commodification of Perinatal Tissue and Maternal Autonomy

Every birth produces a collection of tissues that, until recently, were treated as clinical byproducts. Those tissues now anchor a worldwide market worth billions. Their commercial value rests on real biology, which is why the ethical questions they raise cannot be dismissed as alarmism.

Cord blood, cord tissue (Wharton's jelly), the placenta including the amnion and chorion, and amniotic fluid are distinctive biological materials. They are produced in abundance at every birth, they carry none of the legal, ethical, or moral concerns attached to embryonic sources, and they contain several cell types with genuine therapeutic potential. The peer-reviewed literature identifies four main populations: hematopoietic stem and progenitor cells, endothelial progenitor cells, mesenchymal stem and stromal cells, and human amnion epithelial cells. Each carries a distinct therapeutic profile, and that diversity is what makes perinatal tissue attractive to researchers and companies alike.

Yet the range of established applications is far narrower than the market implies. The single use with a settled clinical record approved by a national medicines regulator is hematopoietic stem cell transplantation for hematological malignancies, bone marrow failure, congenital immunodeficiency syndromes, hemoglobinopathies, and inherited metabolic diseases. The same review notes that non-homologous uses of hematopoietic stem cells, and the clinical applications of the other perinatal cell types, remain under investigation rather than part of the standard of care. The biology is real. The clinical translation is partial.

This distinction matters because it shaped the commercial trajectory. As cord blood research pivoted toward manufacturing off-the-shelf cell and gene therapies, large, well-characterized inventories became valuable to pharmaceutical and biotechnology firms, not only to individual families. The tissues that a mother produces in the delivery room acquired a second life as raw material for an industry whose scale owed more to market construction than to any expansion in what those tissues were proven to do.

How a clinically narrow resource became a multi-billion-dollar industry

The commercial expansion outpaced the clinical evidence at every step. Cord tissue storage appeared as a commercial service in 2008, placental blood storage in 2006, and placental tissue storage in 2011. A product category built on one established transplant application grew into a portfolio of speculative storage services marketed to expectant parents.

Peer-reviewed analysis confirms what this structure implies about use rates. By 2024, more than 8.1 million units sat in private banks worldwide against a fraction of that number in public banks. Public banks, which make units available for unrelated patients who need them, operate on a different logic entirely, and they hold far less inventory.

Market consolidation has reinforced rather than corrected this dynamic. The literature notes the emergence of hybrid models in which privately stored cord blood is made available to the public, but the dominant structure remains proprietary storage financed by individual families. The economics keep the tissue in private hands, where its public health value is contingent on the family's choices rather than on any clinical allocation principle.

The chain now extends well past the birth room, and that extension sharpens the question of who captures the value. The product carries no established benefit-sharing mechanism for the maternal donors whose tissue is the raw material. A mother deciding about cord blood at delivery has no visibility into the downstream products manufactured from placental tissue under her care, and no claim on the value they generate.

Why the gap between established use and marketed promise matters ethically

The ethical problem begins with an information asymmetry that operates on uniquely vulnerable subjects. A pregnant person makes an irreversible decision in an emotionally heightened context, against a commercial counterparty with strong incentives to emphasize speculative benefit. That asymmetry is not incidental to the business model. It is the mechanism through which the business model works.

BMC Medical Ethics identifies the dynamic directly. The concern is not hypothetical. The Arizona Attorney General filed a case against Cord Blood Registry in 2025 accusing the company of misleading parents with unbacked promises of stem cell treatment for more than 80 rare diseases while omitting how rarely those diseases occur. CBR's defense, that its claims are made online by a company with national presence and therefore cannot be subject to local law, reveals a regulatory evasion strategy built into the business model itself.

The evidentiary infrastructure supporting marketing claims can also be manufactured. A BMJ investigation in July 2024 examined Cells4Life, which describes itself as the UK's largest cord blood banking provider, and found the company citing a journal article published within weeks of receipt, with two listed editors who confirmed they did not hold those roles. The scientific apparatus that should discipline marketing instead becomes another surface on which marketing operates.

Researchers Charles Murry of the University of Southern California's Keck School of Medicine and Pietro Merli of Bambino Gesù Pediatric Hospital state the problem plainly. The industry's list of treatable applications rests on late-1990s cellular plasticity claims that have been, in their words, very rigorously disproven. The midwifery literature adds a further point: disclosures should consider the opportunity costs of storing privately instead of donating to a public bank and thereby possibly contributing to a life-saving therapy for someone else. That consideration does not appear in private bank marketing materials, and its absence is the clearest measure of how far the information environment has drifted from what a genuinely informed decision would require.

How "intensive mothering" ideology converts commercial pressure into felt obligation

Private cord blood banking is presented to expectant parents as biological insurance against future disease. The framing matters. It is not sold as a consumer choice among competing goods but as an expression of parental responsibility and love for the child. The purchase becomes legible as something a good parent does, and the transaction absorbs moral weight that a storage service, evaluated on its own clinical merits, could not carry.

This framing exploits what feminist scholars have analyzed as intensive mothering ideology: the expectation that a good mother exhausts every available precaution regardless of evidence, cost, or trade-off. Under this ideology, declining to bank privately does not feel neutral. It is experienced as choosing to do less for one's child, even when the clinical evidence and the opportunity cost analysis both support donation to a public bank or no banking at all.

The ideology also obscures a direct physical trade-off. Commercial cord blood collection competes with deferred cord clamping because longer delays substantially reduce the blood volume available for collection. A mother who chooses to bank may not know that she is choosing between her newborn's immediate circulatory benefit and a stored unit whose future utility is uncertain.

The ideology thus operates in two directions simultaneously. It pressures the mother toward private banking while suppressing information about what that choice forecloses, both for her newborn in the delivery room and for the public supply that could treat unrelated patients. The pressure is not overt. It is embedded in the default assumption that a responsible mother banks privately, and in the silence about what the alternative would have provided.

What maternal autonomy actually requires in this context and why legal ownership frameworks fail to deliver it

Genuine autonomy in this context requires more than the absence of overt coercion. It requires accurate information about proven versus speculative benefits, disclosure of opportunity costs and physical trade-offs, and a decision environment not structured by commercial interest in a particular outcome. None of those conditions is met by default in the current system, and the legal baseline makes matters worse.

Academic analysis establishes that the legal status of the placenta is often ambiguous and varies by country. In many jurisdictions it is classified as medical waste, not as a body part or organ, and is entrusted to the healthcare facility for disposal, usually with only implicit or explicit maternal consent. The structural consequence is a default that transfers control of a maternal body product away from its source without requiring an explicit choice. The default is institutional disposal, not maternal custody.

Regulatory oversight does not close this gap. FDA regulation of cord blood for personal use requires establishment registration, donor screening, infectious disease testing, reporting and labeling compliance, and current good tissue practice. Those requirements govern the safety of the product, not the quality of the decision made by the person whose body produced it. A system can be fully compliant with tissue safety regulations while still marketing speculative benefits to a vulnerable consumer in a way that undermines her ability to make a genuinely informed choice. The regulatory framework protects the tissue. It does not protect the person.

The midwifery literature places the burden of correction on midwives and obstetric providers as the people best positioned to give balanced, evidence-based information. But that only works if providers themselves are equipped and structurally supported to do so, rather than deferring to materials produced by the banks. Autonomy, in this domain, is not something a consent form can capture. It is a property of the information environment, the legal default, and the provider relationship together, and the current system underdelivers on all three.

The strongest defense of the current system and where it falls short on autonomy grounds

The most credible industry defense has two parts. Second, hybrid models, in which privately stored cord blood is made available to the public, represent a convergence of private and public interest. Both claims deserve to be taken seriously. Peer-reviewed analysis confirms that hybrid models are a real and growing phenomenon, and the research value of well-maintained private inventories is not zero. FDA oversight, even if it focuses on product safety rather than marketing claims, imposes real compliance burdens that distinguish legitimate operators from fraudulent ones.

None of this defense addresses the autonomy question. Whether private banking generates research value is separate from whether a pregnant woman choosing a private bank over public donation, or over deferred cord clamping, is doing so on the basis of accurate, complete, and unpressured information. A system can generate genuine scientific value and still systematically undermine the autonomy of the people whose bodies make it possible. The two conditions are not mutually exclusive, and conflating them allows the industry to answer autonomy critiques with utility arguments that are beside the point.

The public banking supply problem illustrates what is at stake. Public banks are experiencing financial difficulties and in some cases closing, which progressively narrows the pool of allogeneic units available for unrelated patients. The defense of the current system rests on benefits that accrue to the industry and to research, while the costs accrue to public supply and to the integrity of maternal decision-making. The ledger does not balance.

What centering maternal autonomy would change in practice

Centering maternal autonomy does not mean opposing banking or dismissing the clinical potential of perinatal stem cells. It means restructuring the decision environment so that consent is genuinely informed and unpressured rather than commercially engineered. The changes that follow are concrete and identifiable.

The requirements are fourfold. Disclose the deferred cord clamping trade-off before commercial collection. Disclose the opportunity cost of private versus public storage. Limit marketing claims to what regulatory and peer-reviewed evidence supports. Each of these is a procedural change, and each directly addresses a documented failure in the current environment. The midwifery editorial literature identifies a direct link between women's level of informed knowledge and the quality of their cord blood banking decisions, which makes provider education and structured counseling a practical lever rather than merely an ethical aspiration.

The legal default on placental ownership is a structural reform target. Shifting from opt-in maternal custody to a framework that requires explicit, informed consent for any institutional use of placental tissue would bring the legal structure into alignment with the principle that the person who produced the tissue has the primary claim over its disposition. The change is not radical. It simply reverses a default that currently runs in the institution's favor.

Perinatal tissue banking has legitimate scientific potential: expanded public inventories, better-characterized cell therapy starting materials, sustainable public bank infrastructure. Realizing that potential requires social trust, and social trust requires that the people at the center of the system experience it as one that respects rather than exploits their position. A banking model that empowers the birthing person to make a genuine choice, including the choice to donate publicly, to defer cord clamping, or to decline any commercial arrangement, is not a constraint on the industry's potential. It is the ethical foundation that makes the industry's long-term claims to legitimacy credible.